Johnson & Johnson Aktie
| 131,06EUR | 3,86EUR | 3,03% |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,86 |
| The Vanguard Group, Inc. | 8,66 |
| Vanguard Group, Inc. (Subfiler) | 8,22 |
| State Street Corp. | 5,47 |
| Vanguard Total Stock Market Index Fund | 2,83 |
| BlackRock Institutional Trust Co. NA | 2,35 |
| BlackRock Fund Advisors | 2,35 |
| Vanguard 500 Index Fund | 2,01 |
| Geode Capital Management LLC | 1,52 |
| Wellington Management Co. LLP | 1,35 |
| State Farm Investment Management Corp. | 1,31 |
| Northern Trust Corp. | 1,24 |
| Massachusetts Financial Services Co. | 1,07 |
| Norges Bank (13F) | 1,05 |
| Government Pension Fund - Global (The) | 1,03 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 126 400 | 134 000 | 135 100 | 132 200 | 134 500 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,57 | 0,57 | 0,60 | 0,62 | 0,61 |
Bilanz (in Mio. EUR) - Aktiva
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 65 032 | 43 088 | 46 033 | 45 274 | 51 237 |
| Summe Anlagevermögen | 97 544 | 94 741 | 90 232 | 88 152 | 99 644 |
| Summe Aktiva | 141 208 | 157 303 | 152 954 | 157 728 | 174 894 |
Bilanz (in Mio. EUR) - Passiva
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 27 126 | 34 581 | 30 480 | 28 681 | 36 366 |
| Summe Fremdkapital | 70 790 | 97 143 | 93 202 | 98 257 | 111 616 |
| Summe Eigenkapital | 70 418 | 60 160 | 59 752 | 59 471 | 63 278 |
| Summe Passiva | 141 208 | 157 303 | 152 954 | 157 728 | 174 894 |
Adresse
| One Johnson & Johnson Plaza, 08933 New Brunswick | |
| Telefon | +1 (732) 524-0400 |
| Internet | http://www.jnj.com |
Management
|
A. Eugene Washington
Independent Director |
|
Alex Gorsky
Chairman & Chief Executive Officer |
|
Anne M. Mulcahy
Lead Independent Director |
|
Ashley A. McEvoy
Executive VP & Worldwide Chairman-Medical Devices |
|
Charles O. Prince
Independent Director |
|
Chris DelOrefice
Vice President-Investor Relations |
|
Ciro Römer
Company Group Chairman |
|
D. Scott Davis
Independent Director |
|
Euan Stuart Thomson
Global Head-Digital Technology |
|
Frederic H. Moll
Chief Development Officer |
|
Hubert Joly
Independent Director |
|
Ian Edward Lamert Davis
Independent Director |
|
James D. Swanson
Global Chief Information Officer & Executive VP |
|
Jennifer A. Doudna
Independent Director |
|
Jennifer Taubert
EVP & Worldwide Chairman-Pharmaceuticals |
|
Joaquin Duato
Vice Chairman-Executive Committee |
|
Joseph J. Wolk
Chief Financial Officer & Executive Vice President |
|
Kathleen M. Widmer
Chairman-Consumer North America |
|
Lisa Romanko
Senior Director-Investor Relations |
|
Marillyn A. Hewson
Independent Director |
|
Mark Alan Weinberger
Independent Director |
|
Mark B. McClellan
Independent Director |
|
Mary C. Beckerle
Independent Director |
|
Mathai Mammen
Head-Science & Development |
|
Matthew Orlando
Secretary |
|
Matthew Stuckley
Senior Finance Director |
|
Michael E. Sneed
Chief Communication Officer & Executive VP |
|
Michael H. Ullmann
Executive Vice President & General Counsel |
|
Nadja Y. West
Director |
|
Paulus Stoffels
Chief Scientific Officer |
|
Peter M. Fasolo
Chief Human Resources Officer & Executive VP |
|
Peter Shen
Global Head-Research & Development |
|
Robert J. Decker
Chief Accounting Officer & Controller |
|
Ronald A. Kapusta
Chief Accounting Officer & Controller |
|
Ronald A. Williams
Independent Director |
|
Sarah L. Colamarino
Vice President-Corporate Equity |
|
Scott White
Company Group Chairman |
|
Thomas J. Spellman
Secretary |
